Venetoclax/Venetoclax Price Trend: Analysis of Market Prices and Medical Insurance Access to 2025

As an important anti-tumor drug, Venetoclax has been officially launched in China and plays a key role in the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Currently, common specifications of venetoclax on the market include 10mg 14 tablets, 50mg 7 tablets, 100mg 14 tablets, and 100mg 4 tablets*7 tablets and other dosage forms. The price range of these products is roughly between 1,000 yuan and 4,000 yuan, and the specific prices vary depending on different specifications and sales channels. At the same time, the drug has been included in the Class B medical insurance reimbursement list, but it can only be used by eligible adult acute myeloid leukemia patients, which reduces the financial burden on patients.

In the international market, the selling price of Venekra varies widely. For example, the original drug from Turkey has a specification of 100mg*112 tablets. Each box usually sells for more than 10,000 yuan. The price is high and is obviously affected by exchange rate fluctuations. This puts some patients under greater financial pressure when choosing to purchase, especially if they require long-term medication.

It is worth noting that with the widespread use of venetoclax, a number of generic drugs have appeared on the market. The ingredients of these generic drugs are basically the same as the original drugs, which can provide patients with more choices. For example, the 100mg*120-tablet generic version of Venetaclav produced by a Lao pharmaceutical factory sells for about 1,000 yuan per box. Compared with the original drug, its price advantage is obvious. This situation provides substantial assistance to patients who wish to reduce their medical costs.

When considering drug choices, patients need to weigh the pros and cons of brand-name drugs versus generics. Although originator drugs are often more stringent in terms of development and quality control, generic drugs can be equally effective in meeting treatment needs. Therefore, patients should consult their doctors when making choices and make reasonable decisions based on their own condition and financial situation.

Reference materials:https://www.venclexta.com/